BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30207092)

  • 1. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.
    Baek MH; Kim DY; Kim SO; Kim YJ; Park YH
    J Gynecol Oncol; 2018 Nov; 29(6):e82. PubMed ID: 30207092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
    Harding BN; Delaney JA; Urban RR; Weiss NS
    Gynecol Oncol; 2019 Aug; 154(2):426-431. PubMed ID: 31178150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Heitz F; Hengsbach A; Harter P; Traut A; Ataseven B; Schneider S; Prader S; Kurzeder C; Sporkmann M; du Bois A
    Gynecol Oncol; 2017 Jan; 144(1):181-186. PubMed ID: 27863705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study.
    Park JY; Lim MC; Baek MH; Park YH; Kim S
    J Gynecol Oncol; 2021 Jul; 32(4):e65. PubMed ID: 34085799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of beta blockers on epithelial ovarian cancer survival.
    Diaz ES; Karlan BY; Li AJ
    Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study.
    Johannesdottir SA; Schmidt M; Phillips G; Glaser R; Yang EV; Blumenfeld M; Lemeshow S
    BMC Cancer; 2013 Feb; 13():85. PubMed ID: 23433478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
    Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
    Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
    Minlikeeva AN; Freudenheim JL; Cannioto RA; Szender JB; Eng KH; Modugno F; Ness RB; LaMonte MJ; Friel G; Segal BH; Odunsi K; Mayor P; Zsiros E; Schmalfeldt B; Klapdor R; Dӧrk T; Hillemanns P; Kelemen LE; Kӧbel M; Steed H; de Fazio A; ; Jordan SJ; Nagle CM; Risch HA; Rossing MA; Doherty JA; Goodman MT; Edwards R; Matsuo K; Mizuno M; Karlan BY; Kjær SK; Høgdall E; Jensen A; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LF; Kupryjanczyk J; Berchuck A; Chang-Claude J; Diergaarde B; Webb PM; Moysich KB;
    Cancer Causes Control; 2017 May; 28(5):469-486. PubMed ID: 28293802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
    Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
    Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of preadmission treatment with calcium channel blockers or beta blockers on short-term mortality after stroke: a nationwide cohort study.
    Sundbøll J; Schmidt M; Horváth-Puhó E; Christiansen CF; Pedersen L; Bøtker HE; Sørensen HT
    BMC Neurol; 2015 Mar; 15():24. PubMed ID: 25884780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients.
    Song HJ; Lee J; Kim YJ; Jung SY; Kim HJ; Choi NK; Park BJ
    Bone; 2012 Dec; 51(6):1008-15. PubMed ID: 22960238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
    Spilsbury K; Tuesley KM; Pearson SA; Coory MD; Donovan P; Steer CB; Stewart LM; Pandeya N; Jordan SJ
    J Clin Oncol; 2023 Jan; 41(2):266-275. PubMed ID: 36001852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly.
    Teichert M; de Smet PA; Hofman A; Witteman JC; Stricker BH
    Drug Saf; 2007; 30(6):541-9. PubMed ID: 17536880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
    Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
    Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical beta-blockers and mortality.
    Müskens RP; Wolfs RC; Witteman JC; Hofman A; de Jong PT; Stricker BH; Jansonius NM
    Ophthalmology; 2008 Nov; 115(11):2037-43. PubMed ID: 18801580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC).
    Le Bozec A; Brugel M; Djerada Z; Ayad M; Perrier M; Carlier C; Botsen D; Nazeyrollas P; Bouché O; Slimano F
    Front Pharmacol; 2023; 14():1137791. PubMed ID: 37274119
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
    BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gonzalez R; Gockley AA; Melamed A; Sugrue R; Clark RM; Del Carmen MG; Growdon W; Berkowitz RS; Horowitz NS; Worley MJ
    Gynecol Oncol; 2020 Jun; 157(3):700-705. PubMed ID: 32222327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Hanley GE; Kaur P; Berchuck A; Chase A; Grout B; Deurloo CM; Pike M; Richardson J; Terry KL; Webb PM; Pearce CL
    Gynecol Oncol; 2021 Aug; 162(2):461-468. PubMed ID: 34090707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.